Cruz HV, León TS, Barragán IG, Martínez LO

Language: Spanish
References: 16
Page: 508-511
PDF size: 230.05 Kb.

ABSTRACT

The zygomycosis widely known as mucormycosis, a rare fungal infection that occurs in immunocompromised patients, such as diabetic ketoacidosis, patients with chemotherapy, immunosuppressive therapy in autoimmune diseases. The site of involvement may be rhinosinusal / rhinocerebral, pulmonary, gastrointestinal and skin. A good prognosis depends on early diagnosis, urgent surgical resection, adequate antifungal treatment and metabolic stabilization.

REFERENCES

1. Douglas MM. Bennett's Principles and Practice of Infectious Diseases. 7th ed. Agents of Mucormycosis and Entomophthoramycosis. 2009;3257-3269.

2. Ribes JAC, Vanover S, Baker DJ. Zygomycetes in Human Disease. Clinical Microbiology Reviews 2000;236-301.

3. Cecil Texbook of Medicine. 23th ed. Mucormycosis, 2011;1994- 1997.

4. Gupta S, Koirala J, Khardori R, et al. Infections in Diabetes mellitus and Hyperglycemia. Infect Dis Clin N Am 2007;21:617-638.

5. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004;10(Suppl. 1): 31-47.

6. Romero-Zamora JL, Sánchez JC, et al. Mucormicosis rinocerebral. Reporte de doce casos. Revista Médica del Hospital General de México 2000;63(3):178-184.

7. Waizel-Haiat S, Cohn-Zurita F, Martín-Vargas A, et al. Mucormicosis rinocerebral invasora crónica. Cir y Ciruj 2003;71(2):145-149.

8. Alvarez-Leyva MA, Sánchez-Navarro LM, y col. Mucormicosis. Dermatología cosmética, médica y quirúrgica 2005;3(3):272-275.

9. Petrikkos G, Drogari-Apiranthitou M. Zygomycosis in Immunocompromised non-Haematological Patients. Mediter J Hematol Infect Dis 2011;3(1):e2011012.

10. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. N Engl J Med 2007;356:348-359.

11. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. N Engl J Med 2007;356:335-347.

12. Spellberg B, Ibrahim AS. Recent Advances in the Treatment of Mucormycosis. Curr Infect Dis Rep 2010;12:423-429

13. Zoller E, Valente C, Baker K, et al. Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Des Devel Ther 2010;4:299-311.

14. Schiller D, Fung H. Posaconazole: An extended-spectrum triazole antifungal agent. Clinical Therapeutics 2010;29:1862- 1886.

15. Tobón AM, Arango M, Fernández D, Restrepo A. Mucormycosis (Zygomycosis) in a Heart-Kidney Transplant Recipient: Recovery after Posaconazole Therapy. Clinical Infectious Diseases 2003;36:1488-1491.

16. Lekakis LJ, Lawson A, Prante J, et al. Fatal Rhizopus Pneumonia in Allogeneic Stem Cell Transplant Patients Despite Posaconazole Prophylaxis: Two Cases and Review of the Literature. Biol Blood Marrow Transplant 2009;15:991-995.